Using data from a nationwide registry, this study revealed significant variation in the use and cost of contemporary regimens for colorectal cancer.
Higher medication adherence among Medicaid beneficiaries with congestive heart failure was associated with lower healthcare utilization and lower costs, and the relationship to costs was graded.
At a symposium at the 77th Scientific Sessions of the American Diabetes Association, experts suggested that the relationship between heart failure and diabetes is finally getting the attention it deserves.
This multicenter study identifies patient complexity in the hospital setting as frequent and helps to better understand what makes a patient complex.
The University of Best Practices physician organization learning collaborative in San Diego County was associated with lower hospitalization rates for heart attacks.
The authors of the manuscript “Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population” respond to a letter to the editor.
Amy Byer Shainman narrates how the knowledge that she was BRCA1 positive led to her decision to undergo prophylactic surgery.
Health information technology that is implemented as part of a multifaceted quality improvement initiative can lead to improvements in hypertension care and outcomes.
Pharmacy and medical claims data showed that patients whose clinicians had access to pharmacogenetic test results had increased adherence and overall cost savings.
A randomized controlled trial was conducted to assess whether adding a peer testimonial to a mailing increases conversion rates from brand name prescription medications to lower-cost equivalents.
Frequent emergency department (ED) users gave similar reasons for using the ED rather than a clinic compared to other patients, including concerns around convenience, access, and quality.
A community-based care management program for high-risk patients reduced hospital readmissions and also likely reduced admissions and Medicare parts A and B spending.
The authors observed a marked shift toward treatment of higher-risk subsets of younger postmenopausal women (with prior fracture and/or with osteoporosis), and away from women at lower risk.
There is significant heterogeneity in formulary placement and restrictions on new drug approvals in the Part D marketplace.
For cost-effective cures, the drug pricing policy challenge is not simply to lower prices, but also to spread the drug costs among payers.